Drugs

The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis
pp. 613-620(8)
Authors: Camussi G.; Lupia E.

Colloid Volume Expanders: Problems, Pitfalls and Possibilities
pp. 621-630(10)
Authors: Roberts J.S.; Bratton S.L.

Chronotherapeutics for Cardiovascular Disease
pp. 631-643(13)
Authors: Anwar Y.A.; White W.B.

An Overview of Topical Antifungal Therapy in Dermatomycoses: A North American Perspective
pp. 645-674(30)
Authors: Gupta A.K.; Einarson T.R.; Summerbell R.C.; Shear N.H.

A Review of the Drug Treatment of Cachexia Associated with Cancer
pp. 675-688(14)
Authors: Gagnon B.; Bruera E.

Guidelines to Reducing Delays in Administration of Thrombolytic Therapy in Acute Myocardial Infarction
pp. 689-698(10)
Author: Williams W.L.

Diagnosis and Treatment of Whipple's Disease
pp. 699-704(6)
Author: Singer R.

Tazarotene
pp. 705-711(7)
Authors: Foster R.H.; Brogden R.N.; Benfield P.

Tazarotene: A Viewpoint by Jonathan Rees
pp. 712-712(1)
Author: Rees J.

Tazarotene: A Viewpoint by Marius Rademaker
pp. 712-712(1)
Author: Rademaker M.

Eprosartan
pp. 713-718(6)
Authors: McClellan K.J.; Balfour J.A.

Eprosartan: A Viewpoint by Anders Himmelmann
pp. 719-720(2)
Author: Himmelmann A.

Eprosartan: A Viewpoint by Norman Sharpe
pp. 719-720(2)
Author: Sharpe N.

Eprosartan: A Viewpoint by William H. Frishman
pp. 719-720(2)
Author: Frishman W.H.

Zanamivir
pp. 721-725(5)
Authors: Waghorn S.L.; Goa K.L.

Zanamivir: A Viewpoint by Douglas M. Fleming
pp. 726-727(2)
Author: Fleming D.M.

Zanamivir: A Viewpoint by Jennifer L. McKimm-Breschkin
pp. 726-727(2)
Author: McKimm-Breschkin J.L.

Abacavir
pp. 729-736(8)
Authors: Foster R.H.; Faulds D.

Abacavir: A Viewpoint by Daan W. Notermans
pp. 737-738(2)
Author: Notermans D.W.

Abacavir: A Viewpoint by Walter T. Hughes
pp. 737-738(2)
Author: Hughes W.T.